19.83
-0.21(-1.05%)
Currency In USD
| Previous Close | 20.04 |
| Open | 19.9 |
| Day High | 20.61 |
| Day Low | 19.66 |
| 52-Week High | 29.56 |
| 52-Week Low | 7.65 |
| Volume | 2.48M |
| Average Volume | 902,720 |
| Market Cap | 1.4B |
| PE | -6.84 |
| EPS | -2.9 |
| Moving Average 50 Days | 23.55 |
| Moving Average 200 Days | 19.91 |
| Change | -0.21 |
If you invested $1000 in Nurix Therapeutics, Inc. (NRIX) since IPO date, it would be worth $1,043.14 as of December 21, 2024 at a share price of $19.83. Whereas If you bought $1000 worth of Nurix Therapeutics, Inc. (NRIX) shares 3 years ago, it would be worth $676.79 as of December 21, 2024 at a share price of $19.83.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
GlobeNewswire Inc.
Dec 19, 2024 12:00 PM GMT
Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom’s MacroglobulinemiaSAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharma
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting
GlobeNewswire Inc.
Dec 09, 2024 11:00 PM GMT
Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments Treatment responses observed in heavily pre-treated population
Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting
GlobeNewswire Inc.
Dec 02, 2024 12:00 PM GMT
SAN FRANCISCO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, toda